Slides
Page 1
© Genmab 2024 Quarter End Results Period Ended September 30, 2026
Page 2
© Genmab 2026 Forward-looking Statements and Non-IFRS Financial Information This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward-looking statements are based upon assumptions of future events which may not prove to be accurate. The forward-looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. This presentation includes certain non-international financial reporting standards (“IFRS”) financial measures that we use to describe the Company’s performance. The non-IFRS Q3 2026 Results financial measures are provided as supplemental information and are presented because management has evaluated the Company’s financial results both including and excluding the adjusted items and believes that the non-IFRS financial measures presented portray the results of the Company’s baseline performance, supplement or enhance management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods. The non-IFRS information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related IFRS measures. Moreover, other companies may define non-IFRS measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. For Investor audience only. Not for public information or use. Not for promotional use
Page 3
© Genmab 2026 22% total revenue growth First Nine Months 2026: Strong Execution and Long-term Value Creation 3For Investor audience only. Not for public information or use. Not for promotional use Focused investments & delivering on our financial commitments 9% adj. operating profit growth* Petosemtamab: positive Phase 3 LiGeR-HN1 results in combination with pembrolizumab in 1L HNSCC; positive Phase 2 results in 1L HNSCC and CRC; <11 months from acquisition closing Epcoritamab: positive Phase 3 EPCORE® DLBCL-2 results in combination with R-CHOP in 1L DLBCL; 3rd Phase 3 readout of 2026 *Does not include acquisition- and integration-related charges and amortization of intangibles acquired through acquisitions. See “Forward-Looking Statements and Non-IFRS Financial Information” Rina-S®: positive Phase 2 (RAINFOL -01) and Phase 3 (RAINFOL -02) results in 2L+ PROC; ~2.5 years from acquisition R-CHOP = rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone; 1L = frontline; DLBCL = diffuse l arge B-cell lymphoma; 2L+ = second line plus; PROC = platinum-resistant ovarian cancer; HNSCC = head and neck squamous cell carci noma; CRC = colorectal cancer
Page 4
© Genmab 2026 4 Positive Phase 3 Readouts Create Multiple Paths for Growth EPKINLY® Expansion plus Two Wholly Owned Assets Create Multiple Potential Approval and Launch Opportunities in 2027 EPKINLY® Co-developed with AbbVie PHASE 3 READOUT EPCORE® DLBCL-2 met its PFS endpoint in 1L DLBCL (HR 0.49). VALUE UNLOCK Potential 1L DLBCL expansion supports EPKINLY® as the core therapy in B-cell malignancies. >$3Bn peak sales potential Rina-S® Wholly owned PHASE 3 READOUT RAINFOL -02 met its primary PFS endpoint (ITT HR 0.29, PAS HR 0.33) in PROC plus secondary endpoint of OS (ITT HR 0.43, PAS HR 0.44). Benefit in patients with PROC irrespective of FRα level or prior treatment with mirvetuximab. VALUE UNLOCK Potential first launch opportunity in PROC. >$2Bn peak sales potential Petosemtamab Wholly owned PHASE 3 READOUT At interim analysis LiGeR-HN1 met its dual endpoints of OS (HR 0.50) and ORR, regardless of HPV status. VALUE UNLOCK HNSCC anchors a wholly owned franchise, with two Phase 3 CRC expansion trials. Multi-$Bn peak sales potential Sources: Genmab Company Announcements. Peak sales: Genmab estimates. Phase 3 results are reported at topline; further details will be presented at an appropriate medical conference. For Investor audience only. Not for public information or use. Not for promotional use PFS = progression free survival; ITT = intent-to-treat, all randomized patients with PROC, regardless of FRα expression; PAS = primary analysis set, mandated patients with FRα expression ≥75% PS2+ to have been treated with mirvetuximab; OS = overall sur vival; ORR = objective response rate; HR = hazard ratio
Page 5
© Genmab 2026 Strong Growth for Proprietary Medicines in 9mo 2026 GLOBAL SALES OF PROPRIETARY MEDICINES1 9mo HIGHLIGHTS 5 9mo 2025 9mo 2026 +37% 1. Total combined net sales for EPKINLY/TEPKINLY and TIVDAK in given time period. $453M $622M Proprietary portfolio delivered accelerated growth in 9mo 2026, reaching an increasing number of patients Proven launch execution is growing adoption across the portfolio, demonstrating commercialization strength Well positioned to drive long-term growth with positive Phase 3 results for priority growth drivers For Investor audience only. Not for public information or use. Not for promotional use
Page 6
© Genmab 2026 Performance Underscores Strength of Antibody Science and Launch Execution Across Markets 6 GLOBAL SALES OF PROPRIETARY MEDICINES 9mo HIGHLIGHTS TIVDAK® • TIVDAK® is the global standard of care in recurrent and metastatic cervical cancer • US market leader in r/m cervical cancer • Encouraging performance across launch markets with readiness well underway in additional markets EPKINLY® • EPKINLY® is the #1 prescribed BsAb in lymphoma globally • Only BsAb approved in both DLBCL and FL indications • Strong growth in 9mo globally; Accelerated uptake in the community driven by 2L FL launch and removal of 24-hour hospitalization recommendation for 3L+ R/R DLBCL • Positive Phase 3 results in 1L and 2L DLBCL poisedto drive growth for the brand globally 9mo 2026 YoY $491M +47% $131M +9% For Investor audience only. Not for public information or use. Not for promotional use
Page 7
© Genmab 2026 Delivering Our Next Phase of Growth Go-to-market capabilities in place to support portfolio expansion Proven launch execution across markets and leading brand positions achieved Clear focus on achieving optimal patient access to medicines Highly effective field execution delivering seamless customer experiences in hematology and solid tumors COMMERCIALIZATION ENGINE BUILT FOR GROWTH COMPELLING GROWTH PORTFOLIO • DLBCL is the most common form of NHL • 1L DLBCL is the largest NHL patient opportunity • 70,000 1L DLBCL patients diagnosed annually EPKINLY® (1L DLBCL) • PROC is a challenging to treat disease • 40,000 women diagnosed annually • Rina-S would become the second asset in gyn- onc portfolio RINA-S® (PROC) • HNSCC is 7th most common cancer globally • 41,000 patients newly diagnosed annually • Petosemtamab would broaden the solid tumor portfolio PETOSEMTAMAB (1L HNSCC) For Investor audience only. Not for public information or use. Not for promotional use 7
Page 8
© Genmab 2026 First Nine Months of 2026: Sustained Growth and Disciplined Investment 8 9mo 2025 9mo 2026 USD 1,016M USD 1,108M Adjusted Operating Profit* 22% Revenue Growth Focused Investments 9% Adj. Operating Profit Growth* 83% 13% 4% 9mo 2025 83% 15% 2% 9mo 2026 USD 2,662M USD 3,238M Royalties Net Product Sales/Collab. Rev. Milestones/Reimb./License Rev. 9mo 2025 9mo 2026 USD 1,489M USD 1,896M Adjusted Operating Expenses* Strong execution drove another quarter of durable growth across markets Continued improvement in revenue quality and diversification Continue to deliver on our financial commitments *Does not include acquisition- and integration-related charges and amortization of intangibles acquired through acquisitions. See “Forward-Looking Statements and Non-IFRS Financial Information” For Investor audience only. Not for public information or use. Not for promotional use
Page 9
© Genmab 2026 2026 Guidance Maintained: Revenue Growth Funds Strategic Investment 19% total revenue growth** and strong profitability • EPKINLY® and continued momentum in royalty portfolio supports growth and revenue quality Planned & focused investments • Increase driven by acceleration of late-stage development for petosemtamab & Rina-S ® and launch readiness activities *Adj. operating expenses and operating profit exclude 2026 charges related to: 1) acquisition and integration-related charges of $90 million and 2) amortization of intangible assets acquired through acquisitions of $47 million. See “Forward-Looking Statements and Non-IFRS Financial Information” **At the mid-point Maintain Strong Profitability while Investing for Future Growth 9For Investor audience only. Not for public information or use. Not for promotional use USD Millions 2026 Guidance* 2026 Guidance Mid-point* Revenue 4,325 - 4,525 4,425 Gross Profit 4,015 - 4,195 4,105 Adj. Operating Expenses (2,810) - (2,950) (2,880) Adj. Operating Profit 1,065 - 1,385 1,225
Page 10
© Genmab 2026© Genmab 2024 Summary: Strong Financial Foundation Positions Genmab for Growth Growing revenue streams and significant underlying profitability Focused and disciplined investment approach Significant growth opportunities supported by our capital allocation strategy 10© Genmab 2026For Investor audience only. Not for public information or use. Not for promotional use
Page 11
© Genmab 2026 On the Path to Our Next Decade of Durable Growth Sustained Growth 22% total revenue growth, nine months 2026 • Revenue of USD 3,238M, up from USD 2,662M in 2025 • Adj. operating profit up 9% to USD 1,108M* High Potential Late-stage Pipeline 3 unprecedented Phase 3 readouts: EPKINLY ®, Rina-S® and petosemtamab • On track for potential launches in 2027 • Multi-$Bn Peak sales potential Capital Allocation <3.0x target gross leverage by year- end 2027 • Focused Merus integration accelerates value capture • Investment prioritizes late-stage development and launch readiness *Does not include acquisition- and integration-related charges and amortization of intangibles acquired through acquisitions. See “Forward-Looking Statements and Non-IFRS Financial Information”. Peak sales potential: Genmab estimates. For Investor audience only. Not for public information or use. Not for promotional use 11
Page 12
© Genmab 2026 Q&A Upcoming Investor Events 8th Annual Wolfe Research Healthcare Conference, November 10, 2026 Jefferies Global Healthcare Conference, November 19, 2026 Citi Healthcare Conference, December 2, 2026 R&D Update and ASH Data Review, December 16, 2026 JP Morgan Healthcare Conference, January 2027
Page 13
© Genmab 2026 Appendix 13
Page 14
© Genmab 2026 Strategic Partnerships, Collaborations, and Licensing Agreements As part of Genmab’s First Nine Months 2026 Financial Results presentation, we will discuss several products developed in collaboration with strategic partners or that are the result of product or technology licenses with other companies. This slide is an acknowledgement of those relationships. Genmab 50% owned products • EPKINLY® / TEPKINLY® (epcoritamab): AbbVie Inc. • Tivdak® (tisotumab vedotin): Pfizer Inc. Companies developing products created by Genmab or that incorporate Genmab’s innovation: • DARZALEX®, DARZALEX FASPRO® (daratumumab, daratumumab and hyaluronidase-fihj), RYBREVANT® (amivantamab), TECVAYLI® (teclistamab), TALVEY® (talquetamab): J&J • Kesimpta® (ofatumumab): Novartis • TEPEZZA® (teprotumumab): Amgen* For Investor audience only. Not for public information or use. Not for promotional use *Teprotumumab was created by Genmab under a collaboration with Roche and development and commercialization of the product is now being conducted by Amgen under a license from Roche
Page 15
© Genmab 2026 Condensed Income Statement: Nine Months Ended September 30 Reconciliation *Adjusted 2026 operating expenses and adjusted operating profit excludes Merus Acquisition and Integration related charges of $87 million, and amortization of intangible assets acquired through acquisitions of $35 million. See “Forward-Looking Statements and Non-IFRS Financial Information” 15 (USD Millions) 9mo 2026 Actual Result Revenue and Gross Profit Total Revenue 3,238 Royalties 2,699 Net Product Sales and Collaboration Revenue 463 Milestones, Reimbursement and License Revenue 76 Gross Profit 3,004 For Investor audience only. Not for public information or use. Not for promotional use (USD Millions) 9mo 2026 Actual Result 9mo 2026 Adjusted Result* Operating Results Operating Expenses (2,018) (1,896) Operating Profit 986 1,108
Page 16
© Genmab 2026 2026 Guidance Maintained: Revenue Growth Funds Strategic Investment 19% total revenue growth** and strong profitability • EPKINLY® and continued momentum in royalty portfolio supports growth and revenue quality Planned & focused investments • Increase driven by acceleration of late-stage development for petosemtamab & Rina-S ® and launch readiness activities Maintain Strong Profitability while Investing for Future Growth 16For Investor audience only. Not for public information or use. Not for promotional use USD Millions 2026 Guidance* 2026 Guidance Mid-point* Revenue 4,325 - 4,525 4,425 Gross Profit 4,015 - 4,195 4,105 Adj. Operating Expenses (2,810) - (2,950) (2,880) Incl. Acquisition & Integration related Charges and amortization of intangibles acquired through acquisitions (2,930) - (3,090) (3,010) Adj. Operating Profit 1,065 - 1,385 1,225 Incl. Acquisition & Integration related Charges and amortization of intangibles acquired through acquisitions 920 – 1,255 1,088 *Adj. operating expenses and operating profit exclude 2026 charges related to: 1) acquisition and integration-related charges of $90 million and 2) amortization of intangible assets acquired through acquisitions of $47 million. See “Forward-Looking Statements and Non-IFRS Financial Information” **At the mid-point
Page 17
© Genmab 2026 Reconciliation of Net Income to Adjusted Consolidated EBITDA Results of the Last Twelve Months (LTM) – Q3 2026 LTM Q3 2026 Q3 2026 Q2 2026 Q1 2026 Q4 2025 Net Profit $729 $342 $303 $53 $31 Plus/(Less): Corporate tax expense/(benefit) 49 12 (8) 21 24 Plus: Depreciation 61 15 14 16 16 Plus: Amortization 42 12 12 13 5 Plus: Share-based compensation expense 160 38 37 49 36 Plus: Impairment charges 58 26 1 - 31 Plus: Acquisition & Integration related Charges 272 10 32 45 185 Plus/(Less): Proforma run rate synergy savings 40 (10) (10) (10) 70 (Less): Financial Income (213) (17) (59) (44) (93) Plus: Financial Expense 479 94 139 150 96 Adjusted Consolidated EBITDA $1,677 $522 $461 $293 $401 17For Investor audience only. Not for public information or use. Not for promotional use
Page 18
© Genmab 2026 Strength of Late-Stage Pipeline: Multibillion-dollar Opportunities Ongoing & Announced Phase 3 Trials 18 For Investor audience only. Not for public information or use. Not for promotional use Program Indication Status Addressable Patient Population* Opportunity (Peak Sales) EPKINLY® 1L DLBCL (EPCORE® DLBCL-2) Data October 2026 70,000 >$3Bn 2L+ DLBCL (EPCORE® DLBCL-1) Data January 2026 21,0002L+ DLBCL (EPCORE® DLBCL-4) Data June 2026 1L FL (EPCORE® FL-2) Ongoing 28,000 2L+ FL (EPCORE® FL-1) Approved in US 9,000 Rina-S® PROC (RAINFOL -02) Data October 2026 40,000 >$2Bn 2L+ EC (RAINFOL -03) Recruiting 14,000 1L pMMR EC (RAINFOL -08) Announced 1 OC (RAINFOL -10) Not yet recruiting 2L PSOC maintenance (RAINFOL -04) Recruiting 25,000 2L PSOC platinum-doublet chemo replacement (RAINFOL -07) Recruiting Petosemtamab 1L HNSCC (LiGeR-HN1) Data October 2026 41,000 $Multibillion 2L+ HNSCC (LiGER-HN2) Ongoing 25,000 1L CRC (LiGER-CRC1) Recruiting 78,000 2L CRC (LiGER-CRC2) Recruiting 101,000 *Genmab Internal, US, JP and EU5